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1. Introduction 
Worldwide there are a large number of patients with diabetes mellitus (DM) and the 
prevalence is increasing rapidly. About 20-30% of patients visiting family practice units 
suffer from DM or its complications. Family physicians require in-depth knowledge of DM. 
A family physician is expected to know about the disease as well as the drugs prescribed to 
treat the disease. They should provide practical and comprehensive care to DM patients. 
The diagnosis of a disease must be easy and less costly and should provide an estimation of 
the risks facing a patient in the future if precautions and recommendations are not adhered 
to. Family physicians need standard algorithms to follow their patients with DM. This 
chapter summarizes simple definitions, routine assessments, standard treatment and 
preventive options that should be known, easily recognized and applied by family 
physicians providing daily care to patients with DM. 
2. History 
Symptoms of DM have been reported since very old times. Diabetes is a word of Greek 
origin and means a “siphon”. Aretus the Cappadocian, a Greek physician who lived in the 
2nd century, named the condition such because his patients had polyuria and passed water 
like a siphon. Mellitus is a Latin word and means “honey”. The combination of these two 
words describes an illness that is associated with frequent and sweet urination. Current 
medical knowledge supports the ancient definition because it is now known that plasma 
glucose levels over 180-200 mg/dL impair glomerular filtration and pollakiuria and 
glycosuria are the result.  
In 2009, the American Diabetes Association (ADA) and European Association for the 
Study of Diabetes (EASD) published a consensus report stating that the A1C can be used 
as a criterion for the diagnosis of DM [ADA, 2012]. Table 1 summarizes the current 
diagnosis approach. The A1C measure defines DM clearly for family physicians and 
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prevents confusion in the diagnosis of patients with DM. There are some other well 
established tests, including the oral glucose tolerance test. However, it takes time to 
obtain a definitive result from this test as repeated blood samples (3-4 over 2-3 hours) are 
required to measure plasma glucose. In addition to diagnosis of DM, the A1C provides 
clues about the possible complications that the diabetic patients may be faced with. The 
A1C is also used to direct treatment options. If the A1C values are within normal limits 
then a decision whether to continue with the ongoing treatment is made. This criterion 
has been the topic of much debate in Medical arena as many authorities do not agree 
with the use of A1C as a diagnostic criterion. It has been argued that the A1C may not 
able to detect DM characterized by postprandial hyperglycemia. Another argument 
relates to the standardization of the A1C measurement techniques used by laboratories. 
Therefore, a standardized method needs to be used, and it is recommended that the A1C 
should be confirmed with fasting plasma glucose (FPG ≥126 mg/dL). However, 
laboratories that serve family physicians are not always set up to measure the A1C. In 
addition, the A1C values may vary depending on race and ethnicity [Ziemer et al. 2010 & 
Kumar et al. 2010].  
 
 FPG 
OGTT 2-h 
PG 
Random PG A1C 
Diabetes 
Mellitus 
≥126 mg/dL 
(7.0 mmol/L) 
≥200 mg/dl 
(11.1 
mmol/L) 
≥200 mg/dl 
(11.1 mmol/L) 
and classic 
symptoms of 
hyperglycemia 
≥6.5% 
(≥48 mmol/mol) 
Increased risk 
for DM 
(prediabetes) 
100-125 
mg/dL 
(5.6-6.9 
mmol/L) 
140-199 
mg/dL 
(7.8-11 
mmol/L) 
 
5.7-6.4% 
(39-46 mmol/mol) 
*[ADA, 2012] 
Table 1. Current criteria for diabetes mellitus diagnosis and increased risk for diabetes mellitus* 
Over the last decade we have observed some major modifications in the treatment 
options related to DM. In 2006, the ADA reported that life-style changes alone are not 
sufficient to overcome DM in individuals recently diagnosed with the disease. Based on 
meta-analyses studies, Metformin has been included as a first line treatment option, if 
no contraindications are present [Nathan et al., 2006]. Metformin has many beneficial 
effects in the treatment of DM and it is very cost effective. Metformin decrease plasma 
glucose (PG) and has been shown to slightly alleviate obesity and reduce elevated blood 
lipids. However, it is well known that metformin is not always well tolerated and 
therefore half the target dose is recommended during the initial stages of metformin 
therapy. Metformin therapy is not recommended for patients with creatinine levels 
exceeding the upper limit of normal range (>1.4 mg/dL) or if eGFR less than 60 
mL/minute. 
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The ADA, supported by the EASD, indicated that a global target for reasonable 
glycemic control should be A1C <7%. However, International Diabetes Federation (IDF), 
the local societies, like Society of Endocrinology and Metabolism of Turkey (SEMT) and 
others suggested a slightly lower target (A1CA1C ≤6.5%) [ADA, 2012; IDF, 2005; SEMT, 
2011]. However, from 2010, individual specifications such as diabetes duration, life 
expectancy, and previous glycemic control status, associated co-morbidities, and 
complications are advised to be taken into account before setting the target of glycemic 
control.  
3. Pathogenesis 
Diabetes Mellitus is characterized by hyperglycemia that results from defects in the 
secretion and/or action of insulin. DM is primarily classified into two groups, type 1 DM 
and type 2 DM. Generally, type 1 DM is accepted as an autoimmune disease with some 
triggering factors usually responsible for the development of autoimmunity. Destruction of 
pancreatic β-cells by several autoantibodies (i.e. islet cell cytoplasmic antibodies; ICA, 
antibodies against glutamic acid decarboxylase; Anti-GAD, islet associated or anti-tyrosine 
phosphatase antibodies; IA2, anti-fogrin antibodies; IA2-β, insulin autoantibodies; IAA, and 
antibodies against zinc transporter-8; Anti-ZnT8) is the typical explanation regarding the 
mechanism for the development of type 1 DM. On the other hand, peripheral insulin 
resistance, loss of β-cell reserve or β-cell exhaustion, problems in hepatic glucose 
production, abnormalities in glucose absorption and obesity are the main pathological 
characteristics of type 2 DM [Barnet & Braunstein, 2007]. 
4. Epidemiology 
DM is a major epidemic of the 21st century. However, reports published in 2010 
demonstrated that the estimated targets for 2025 have already been reached, 15-20 years 
earlier than expected. According to the recent estimates by IDF (IDF Fifth Atlas, 2011), there 
are 366 million people with DM worldwide, and the population with DM is expected to 
increase to 552 million by the year 2030. 
It has been shown that the risk for DM is higher in individuals who have not completed 
formal education as compared with those who received a high school or university 
education. In cross-sectional studies current smoking has been suggested to have a 
protective effect that may be explained by lower caloric intake  or weight loss associated 
with smoking. However, ex-smokers are more prone to developing DM compared with non-
smokers due rapid weight gain [Amorosa et al., 2011]. Recent guidelines decreased the 
diagnostic level for FPG and this increased the number of people diagnosed with DM. In 
addition, a sedentary life-style, poor diet, obesity and the lack of regular physical activity 
contributed to  reaching the 2030 DM estimates early [Satman et al., 2010]. The increased 
prevalence of childhood obesity has been associated with insulin resistance. For children 
born after the year 2000 there is a 32.8% risk of developing DM in males and 38.5% risk in 
females [Amorosa et al., 2011]. 
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5. Routine assessments 
Routine assessments are very important in DM because these allow physicians to monitor the 
development of the disease and associated complications. These assessments provide early 
identification of co-morbidity, risk factors as well as complications of DM that include 
coronary artery disease (CAD), impotence, neuropathy, nephropathy, retinopathy and 
blindness. The combination of neuropathy, retinopathy and nephropathy in DM is termed 
the “triopathy”. Awareness of retinopathy is typically found in individuals who have had a 
family member who experienced the same complication or those actively seeking information 
relating to the complications of DM. Family doctors should inform their patients about the 
danger of complications. They should ensure that the appropriate laboratory examinations 
are performed in time and refer patients to specialists or colleagues if required. A plan for the 
management of DM should be developed and maintained between the physician and the 
patient. Compliance of the patient to the plan should be monitored by the physician. 
5.1. Glycosylated hemoglobin A1C  
The A1C percentage may reflect average glycemic control over several months [Sacks et al., 
2002]. The A1C test helps in the diagnosis of DM and is also valuable for the determining 
the efficacy of treatment. In addition, the test is useful for determining DM complications 
(Table2).  
As we mentioned previously, A1C target levels differ from patient to patient. For the elderly 
and children the aim is not to have a tight control of the A1C level. Tight control may 
disturb quality of life of the patient and it may increase health risks. Immaturity in children 
<6 or 7 years and their inability to recognize hypoglycemia leads to modifications in 
glycemic goals. There is small data available to show benefits of intensive glycemic, blood 
pressure, and lipid control in the elderly [ADA, 2012]. 
 
Type 1 DM (DCCT study) 
Retinopathy 35% ↓ 
Neuropathy 30% ↓ 
Nephropathy 24-44% ↓ 
Type  2 DM (UKPDS study) 
Micro vascular complications 35% ↓ 
Death rate in DM 25% ↓ 
MI 18% ↓ 
Mortality of all causes 7% ↓ 
DM, diabetes mellitus; DCCT, Diabetes Control and Complication Trial; UKPDS, United 
Kingdom prospective Diabetes Study; MI, myocardial infarction. 
Table 2. Relationship between complications and 1% decrease in A1C  
5.2. Microalbuminuria and estimated glomerular filtration rate (eGFR) 
Microalbuminuria measurements can be performed using different methods. Albumin and 
creatinine determination in spot (preferably first morning) urine sample is preferred to 24 
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hour urine analyses [Eknoyan et al., 2003, Levey et al., 2003]. Determination of early 
morning microalbuminuria in spot urine is an easy method that can be obtained in a family 
practice setting but a limitation is that this method is associated with false positives. In 
addition, hydration status affects the test results. However, albumin to creatinine ratio 
(ACR) is less affected by dehydration. Classification of microalbuminuria state is shown in 
table 3.  
Diagnosis of persistent microalbuminuria should occur if positive in two out of three urine 
samples over six months. It should be remembered that exercise in the previous 24 hours, 
infections, congestive heart failure and uncontrolled hypertension may interfere with the 
results. The ADA and EASD recommend microalbuminuria testing at least once a year. 
 
Normal <30  
Microalbuminuria 30-299  
Macroalbuminuria ≥300  
Table 3. Microalbuminuria (ACR; early morning spot urine albumin [μg]/creatinine [g]) 
Estimated glomerular filtration rate (eGFR) is another method for evaluating renal function. 
The Modification of Diet in Renal Disease (MDRD) formula can be used to estimate GFR. 
There are websites for calculating eGFR on the internet. Some laboratories note the results of 
eGFR together with creatinine measurements [Levey et al., 1999]. eGFR <90 mL/minute 
indicates renal failure. 
5.3. Serum cholesterol 
“Diabetic dyslipidemia” is considered in individuals with low HDL-cholesterol and high 
TG. The targets for HDL-cholesterol should be ≥50 for females and ≥40 mg/dL for females, 
and <150 mg/dL for TG. Hyperlipidemia is a common co-morbidity seen in DM. The 
Framingham Heart Study found that DM and hyperlipidemia are major risk factors for the 
development of coronary artery disease. Lipid profiles should be checked every year in 
patients with DM. Precautions should be taken if there is an elevated lipid profile. Low 
density lipoprotein cholesterol (LDL-cholesterol) levels <100 mg/dL must be achieved as 
soon as possible. If there is already a history of coronary artery event then the target for 
LDL-cholesterol should be revised to <70 mg/dL [Grundy et al., 2004]. 
5.4. Fundus examination 
Screening for diabetic retinopathy gained importance after reports that laser 
photocoagulation was very effective in preventing visual loss (DRS Group, 1976). Fundus 
examination by an ophthalmologist at least once in a year is recommended. Some family 
physicians may have experience examining the retina; however it would be better to do so 
in a hospital setting. Examination can be performed using an ophthalmoscope or a slit lamp. 
Fluorescein angiography (FFA) can be used to determine the location of the leakage in 
suspected cases. 
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Diabetic retinopathy is classified as non-proliferative or proliferative in nature. Once a 
retinal hemorrhage has been identified it is recommended, especially for individuals with 
proliferative retinopathy, the assessment should be performed more frequently. 
5.5. Foot examination 
Physicians should examine the feet of DM patients preferably in every visit to help prevent 
the development of the “diabetic foot ulcers”. A careful inspection and palpation of lower 
extremity pulses is required. Skin temperature must be checked and increases or decreases 
in the regular temperature, suggests the existence of an underlying problem. Skin hair loss, 
atrophy, cracked skin, or poor circulation suggests neurotropic or autonomic changes. 
Cracked skin is a haven for infections and a loss of circulation delays wound healing. 
Patients should be educated about these changes. If they notice something abnormal they 
should inform their family physicians about the problem. 
6. Microvascular complications 
Microvascular complications of DM worsen the quality of life and cause increased 
morbidity in patients. These complications include diabetic foot ulcers that family 
physicians should be aware of as well as prevent their progression. In the case of DM related 
end stage renal disease (ESRD), hemodialysis is usually considered. This situation also 
worsens the quality of life for patients with DM. Diabetic retinopathy is the most common 
cause of blindness. However, before reaching the stage of blindness it causes occupational 
and some other serious problems. This in turn affects other members of the family if the 
patient was the only one who works outside. Considering complications in DM it should be 
kept in mind that the first thing to do is to control PG levels and regulate hypertension if it is 
present. This approach will not only prevent most of the complications but also stops the 
progression of the pre-existing complications. 
6.1. Retinopathy  
Excluding traumatic cases, DM is the most common cause of blindness. During the first two 
decades of DM, nearly all the patients with type 1 DM and more than half of the patients 
with type 2 DM experience retinopathy to some degree [Budak et al., 2004]. 
It is possible to diagnose retinopathy while performing routine ophthalmologic examination 
but family doctors should suspect diabetic retinopathy when microalbuminuria is detected 
in the urine. In addition, patients with known CAD have a greater risk of retinopathy. 
Early detection of retinopathy should be one of the priorities when assessing DM patients. 
Early detection ensures a beneficial response to treatment. A FFA verifies the suspected 
retinopathy and photocoagulation is the preferred treatment if the diagnosis is evident. 
Ophthalmologists attempt to coagulate leaking retinal vessels to prevent the progression of 
retinal edema. Improvement in DM retinopathy is associated with reduced PG regulation 
[Klein (1995)] and blood pressure [Leske et al., 2005]. 
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6.2. Neuropathy 
Neuropathy is one of the most common chronic complications of DM (the prevalence over 
20 years duration of DM is approximately 70%) but is usually under diagnosed [Barnett & 
Braunstein 2007]. Duration of DM and poor PG control correlates with the occurrence of 
diabetic neuropathy. Peripheral neuropathy is seen in 30% of cases. Neuropathy of nerves in 
the feet provides the earliest symptoms. Neuropathy has been sub-divided into three groups 
(autonomic, focal, and diffuse). Autonomic neuropathy has three components, 
cardiovascular, gastrointestinal and genitourinary. Examples of focal neuropathies are 
mononeuritis and carpal tunnel syndrome. Proximal motor neuropathy and distal 
symmetric polyneuropathies are diffuse neuropathies. Paresthesia can be described as 
numbness, burning or pins and needles in extremities. A characteristic of paresthesia is that 
the pain increases at night [Amorosa et al., 2011]. 
Analgesics, antiepileptic drugs and antidepressants can be used in the treatment of painful 
neuropathies. Amitriptilin, an antidepressant drug, has been used widely for pain relief in 
painful neuropathic cases. Anticonvulsants such as gabapentin, and pregabalin or SSRIs 
such as duloxetine, are modern pain relief drugs commonly used in painful neuropathies. B 
complex vitamins have also been used to treat neuropathy; however recent studies do not 
support their use. It has been suggested that long term metformin use may cause iatrogenic 
neuropathy due to malabsorption of vitamin B12 [Attarian 2011]. 
6.3. Diabetic foot ulcers 
Diabetic foot ulcers are due to impaired nerve innervations in the lower extremities. This in 
turn causes decreased circulation that result in deficient migration of leukocytes to infected 
areas. Dryness of the extremity causes cracked skin that increases the risk of microorganisms 
settling there. Insufficient immune responses prevent local inflammation and subsequent 
healing. 
Management of mild to moderate cases of diabetic foot should be provided by a foot 
care team including a physician, vascular surgeon, orthopedist, plastic surgeon, 
podiatrist, nutritionist, and physiotherapist. Treatment of advanced diabetic foot ulcers 
requires long hospitalization periods, and is costly. Treatment often requires surgery 
and in some cases the amputation of the affected finger or foot. In certain situations,  
an amputation or revised amputation at a higher level is indicated. Hyperbaric  
oxygen therapy is considered an adjuvant therapy and may be effective in some cases 
[Cimşit et al., 2009]. This therapy enables accelerated circulation to hypoxic, infected or 
ulcerated parts of the foot. Anemia should also be corrected as soon as possible to 
enhance wound healing. A neglected, small injury may cause the loss of a finger, foot  
or a leg. 
The basic approach in DM patients suffering from any complication is prevention. Family 
physicians stand at the center of treatment. They should educate their patients about foot 
care and inform them about importance of PG regulation and advise the cessation of 
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smoking. Patient education also includes information and training about topics such as foot 
inspection, appropriate shoes and socks, nail cutting and the importance of consulting a 
podiatrist [Barnett & Braunstein 2007]. 
6.4. Nephropathy  
The incidence of DM related nephropathy is 20-30% [Barnett & Braunstein 2007]. 
Microalbuminuria and eGFR should be measured every year in patients with DM. When 
macroalbuminuria is diagnosed then a protein restriction diet is recommended. Blocking the 
renin–angiotensin system (RAS) by drugs such as ACE inhibitor or ARB is advised to reduce 
BP, established microalbuminuria and CAD outcomes [HOPE study group 2000]. ESRD is 
the undesired complication if the recommended treatment does not work. ESRD is usually 
treated by hemodialysis. Nephropathy of different stages is not rare in a population, but it is 
often undiagnosed. It is possible to evaluate eGFR if serum creatinine is measured. The 
eGFR results can be used effectively by family physicians for preventing the progression to 
renal failure. Hemodialysis on top of DM can make the life more difficult for diabetic 
patients.  
6.5. Erectile dysfunction 
Erectile dysfunction affects over 50% of men with diabetes >60 years old. Its etiology is 
multifactorial. It was shown that erectile dysfunction may be a signal for silent CAD [Phe & 
Rhoupret 2012]. Sildenafil may be effective in its treatment. However, risk of accompanying 
cardiovascular problems limits sildenafil use. Cessation of smoking should be strongly 
recommended. 
7. Macrovascular complications 
Accelerated atherosclerosis causes macrovascular complications that include CAD, cerebral 
and peripheral vascular diseases. It is not unusual for DM patients to experience a stroke 
more than once. Macrovascular complications are the primary cause of death in patients 
with DM. 
7.1. Hypertension 
When considering macrovascular complications, controlling hypertension is even more 
important than the regulation of hyperglycemia. ACE inhibitors are the first line of therapy, 
despite the finding that ARB and calcium channel blocker drugs may be as effective. The 
target for the reduction of blood pressure is slightly lower than normal (systolic <130 and 
diastolic <80 mmHg). Studies have shown that blood pressure over 115/75 mmHg carries a 
high risk for CAD [Chobanian et al., 2003]. 
On average about three different types of drugs are needed to decrease blood pressure in 
patients with DM. 
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7.2. Coronary artery disease 
The most important complication related to mortality and morbidity in DM is CAD. DM is 
considered a cardiovascular disease equivalent. Major CAD risk factors should be evaluated 
once a year and identified risks (e.g. hyperlipidemia, hypertension, smoking and 
microalbuminuria) should be treated. In general, asymptomatic patients and/or patients 
with a “normal” resting electrocardiogram (ECG) are not recommended for further 
screening for CAD. However, DM patients who have not been diagnosed with CAD are 
considered to have the same risk as non-diabetic CAD patients [Barnett & Braunstein 2007]. 
DM patients diagnosed with CAD risk are recommended to use aspirin. However, based on 
recent meta-analyses aspirin is not routinely recommended for primary prevention of CAD. 
ACE inhibitors and statins should be added to therapy for DM patients with CAD. Post 
Myocardial Infarction (MI) patients are advised to use a β-blocker for at least two years if 
tolerable. 
7.3. Stroke 
About 80% of patients with DM die from stroke or CAD. During a stroke blood supply to 
the brain is reduced resulting in brain tissue damage. Sudden onset paralysis, cognitive and 
speech impairments are observed. Clot dissolving treatment must be started as soon as 
possible. Stroke prevention and treatment requires the reduction of lipids and hypertension. 
Cessation of smoking is mandatory.  
Usually it is not advised to decrease PG levels too quickly especially if long-term poor 
glycemic control exists.  
8. Treatment 
Treatment of DM is multidisciplinary and unique for every patient. The first step of treatment 
in DM is acceptance of the disease. Every patient should receive comprehensive information 
about the seriousness of the disease. Importance of self-care in DM must be stressed. 
Establishment of confidence between the physician and patient should be established before 
treatment algorithms are implemented. The patient should accept that with the help of the 
family physician the disease can be controlled. During face to face interviews patients must 
be made aware that the disease is chronic and that treatment will be life-long. It should be 
emphasized that if precautions are not taken this will increase the risk of complications that 
may increase morbidity and mortality. The patient should be informed that DM may affect 
their quality of life as well as that of their family. On the other hand, the patient should also 
be made aware that DM is a common condition. Its prevalence is assumed to be more than 
10% worldwide and this means that the patient is not alone. The above general 
considerations regarding acceptance of the disease takes time, patience and experience. 
The conventional treatment guidelines recommend metformin administration as soon as the 
diagnosis has been established. Metformin therapy is cost effective. However, for cases 
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where the A1C values >10% and/or FPG >300 mg/dL and/or complaining about severe 
hyperglycemic symptoms then insulin therapy must be commenced immediately. Recently, 
a common approach has been to use a long acting insulin analog injection once daily with or 
without an oral antidiabetic drug. 
Persuading a patient to transfer to the use of insulin is difficult and sometimes impossible. 
The public perception of insulin therapy is poor. Insulin is considered the end of the road 
and some individuals see it as a “poison”.  
In medicine the existence of treatment “fads” or “myths” is ever present. Over-time the 
truth we believe in may turn out to be a false. Physicians should work with evidence-based 
science. Family physicians must be up to date with current DM treatment practices. Insulin 
is the accepted drug used in the treatment of DM. It is claimed that high dose insulins such 
as glargine or NPH, and pioglitazone may be associated with slightly increased risk of some 
kinds of malignancies. Researchers have not been able to link between the development of 
breast cancer and glargine insulin or between bladder cancer cases and pioglitazone. Both of 
these medications are very successful treatment options. 
In daily practice it is not surprising to observe patients that are using two or more different 
kinds of oral antidiabetic drugs despite this not being recommended in the treatment 
guidelines. Unfortunately, patients sometimes use drugs that have the same mechanism of 
action. This may result in hypoglycemia. It is not possible for family physicians to know 
every disease and every drug. However, DM is a common chronic disease and therefore 
family physicians should have comprehensive knowledge of the medication used for all 
stage of the disease. This will increase the physician’s confidence and increase the level of 
confidence between the patient and the physician. 
Resistance to insulin can be classified into three types: Clinical insulin resistance, patient’s 
resistance to insulin injection and physician’s resistance to prescribe insulin. Of these the 
first type is the true biological resistance that plays a role in the development of DM. 
Physicians who are not confident in prescribing insulin therapy should refer their patients to 
an experienced specialist. Any delay in referral may result in harm to the patient and an 
increased risk of developing complications. Research has shown that a 1% drops in the A1C 
will result in a 21% decrease in complications and decrease mortality and morbidity rates in 
DM patients. Keeping patients unaware of suitable therapy such as insulin is not ethical and 
may be considered as malpractice. Hospitalization is not a rule when transferring to insulin. 
If the patient is not critically ill then education about insulin injections can be given at the 
family practice. A physician and/or a nurse trained that has received training in DM care can 
educate the patient. 
It is a common approach to start injecting basal insulin using a dose of 0.2 Units/day. If the 
insulin is a premixed human short acting and long acting then 2/3 of the total dose is 
injected in the morning and 1/3 in the evening. Human insulin mixtures are preferably 
injected 15-30 minutes before the main meal but insulin analogs are injected just 5-15 
minutes before the meal. If a mixture of analog insulins is prescribed, then about 50-60% can 
be given in the morning, and the rest before dinner. Patients should self-monitor their 
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glucose levels and share the results with their physician. Postprandial measures are 
obtained at the end of the second hour following the meal. At the start of treatment, if there 
are no extraordinary problems, the physician evaluates the self monitored results every 
three days and based on these results decides on how to manage the optimal dose of insulin. 
Insulin injections are administered using a special pen that can be adjusted to comfortably inject 
the desired doses. Education on the use of the pen should be provided to the DM patients. 
Family physicians should instruct patients to keep insulin in refrigerator at an optimal 
temperature and not to allow it to freeze. Injection methods should be explained and 
demonstrated in person. A description regarding the use of the insulin pen is provided in the pen 
boxes. However, this may confuse beginners as well as individuals who are scared of injections. 
During the insulin education interview patients may be asked to write down the steps one by 
one in their own words so that at the time of application there is no confusion. It is known that 
insulin absorption is faster around the umbilicus where there is a large amount of vessels. 
Patients must be informed about hypoglycemia. Hypoglycemia usually occurs in response 
to fasting for a long time and/or when individuals perform with extra effort compared with 
normal. Signs of hypoglycemia are cold sweating, tachycardia, blurred vision and changes 
in consciousness. If the physician informs patients about the risk of hypoglycemia before 
they experience it, this may help in the management of hypoglycemia treatment, improving 
trust between the patient and physician. In addition, a better compliance to the treatment 
will be achieved.  
Attempting to determine the optimal insulin dose as soon as possible is not recommended. 
In cases of stroke and retinopathy, smooth increases in insulin doses are advised. Target 
A1C levels may differ in different groups. For example, for the children and the elderly, 
targets are not as low as in adults. Diabetes treatment should not be based on a single 
individual. It must be acknowledged that the diagnosis of DM in a small baby will 
obviously affect the whole family. Sometimes a diabetic woman may be forced to give up 
insulin injections by her husband. If this is the case, family physicians must provide extra 
attention to these patients. Care in DM needs to be directed not only to the patient but also 
to the family and at times, the public. 
9. Noninsulin therapy (drugs)  
9.1. Insulin sensitizers: Biguanids (metformin) 
This medication is recommended as first line therapy in addition to life style modifications. 
It is important to check creatinine levels when using the drug. A creatinine level that is 1.4 
mg/dL, or an eGFR >60 mL/minute is critical when making a decision to discontinue the 
drug. When the drug is used for the first time by a patient a stepwise manner is 
recommended. Half or sometimes one quarter of the dose is started for 3-7 days and then 
increased gradually until the total dose is administered. Gastrointestinal symptoms are 
common if the drug has not been taken 1-2 hours after a meal. Metformin may have a mild 
positive effect on weight loss and is therefore its use is preferred in obese individuals. 
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9.2. Insulin secretagogues: Sulfonylureas (gliclazide) 
Gliclazide is an alternative group of oral antidiabetic drugs. The risk of hypoglycemia is the 
major adverse effect and it may last more than 24 hours. It is usually preferred in patients 
older than 30 years old, who are relatively thin and have had DM for no longer than 5 years.  
Others: 
α-Glucosidase inhibitors (acarbose) 
It has mechanism of action on glucose absorption from gastrointestinal tract. 
Gastrointestinal side effects like flatulence, abdominal discomfort and diarrhea have been 
observed. In elderly it is preferred because there are no serious side effects like 
hypoglycemia when the drug is used alone. 
DPP-4 inhibitors (Sitagliptin) 
These are known as insulin like oral glucose-lowering drugs. They selectively and reversibly 
block degradation of GLP-1 and other incretins. They promote insulin sensitivity and 
improve β-cell function.  
10. Insulin therapy 
10.1. Long acting insulin 
NPH insulin, Glargine insulin and detemir insulin are classified as long acting insulin. The first 
two are recommended once a day but detemir insulin can be used twice a day. If the patient is 
recommended to use insulin once a day, depending on the patient’s reaction, it can be injected 
in the morning or in the evening. To avoid hypoglycemia while sleeping the insulin can be 
injected in the evening but sometimes it works better when injected in the morning. 
10.2. Short acting insulin 
Short acting insulin is primarily used as a part of intensive insulin therapy. Usually it is 
administered three times a day before the meals. Insulin analogues can be injected just 
before the meal. 
10.3. Mixed insulin 
There are different formulations for insulin mixtures. Probably the most commonly used 
formulation is the 30/70 insulin mix that is composed of 30% short acting and 70% long 
acting insulin. It is advised that the insulin is mixed well before use. In general, 2/3 of the 
total daily dose is injected before breakfast and the remaining 1/3 before dinner. The reason 
why it is important to follow this protocol is because during the daytime the patient 
continues to eat but after dinner there may only be a small snack eaten just prior to sleeping. 
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Therefore, to prevent hypoglycemia during the sleep a smaller dose is injected at dinner. 
There are also 50/50, 25/75 and 20/80 combinations. Preferably, the 20/80insulin mix is 
administered in the elderly while the 50/50 combination may be beneficial in diabetic 
patients who perform heavy work as well as individuals who have poor dietary habits. In 
these individuals the mix is injected three times a day. 
10.4. Intensive insulin therapy 
Intensive insulin therapy is indicated on some occasions. Probably the most effective 
method for injecting insulin injection is dividing the total dose into 4-5 administrations. In 
practice this is not comfortable. Physicians usually prefer to divide the total dose of insulin 
into 4 or more administrations when it exceeds 100 Units per day. It is recommended that 
family physicians consult with endocrinologists when intensive insulin therapy is 
considered. 
11. Gestational diabetes mellitus 
Gestational diabetes mellitus (GDM) is diagnosed during the pregnancy and may 
sometimes persist after the baby is born. Family physicians should screen for GDM as soon 
as possible. Screening for GMD is recommended in the general population if risks for 
diabetes are present. If there is no DM risk in the pregnant women a75 g oral glucose 
tolerance test is recommended at 24-28 weeks of gestation. Following labor checking for the 
persistence of DM is recommended. 
GDM carries risks for the mother and baby. Treatment options during the pregnancy are 
limited. 
If GDM cannot be controlled by diet then insulin administration must be considered. Oral 
antidiabetic drugs may be teratogenic. Conventional insulin should be selected for treatment 
because there are not enough clinical data regarding the use of modern insulin analogs. 
12. Immunization  
The Centers of Disease Control and Prevention (CDC) recommend both influenza and 
pneumococcal vaccines for all patients with DM. The ADA also recommends that DM 
patients should be vaccinated against influenza and pneumonia because they are more 
susceptible to these diseases and are typically hospitalized for a longer time than non-
diabetics and have an increased risk of dying. Therefore, the World Health Organization has 
a target to increase the number of DM patients that receive vaccinations to75% against 
influenza and 50% against pneumonia.  
12.1. Influenza vaccine 
Hospitalization due to influenza is three times more common among diabetics who have not 
been vaccinated [Colquhoun et al., 1997]. Hospitalization in intensive care units is four times 
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more likely in unvaccinated cases. Trivalent influenza vaccine is available and contains the 
expected subgroups of influenza in the region for a particular year. A history of anaphylactic 
egg allergy is a contraindication for influenza vaccines. Children under 36 months are 
vaccinated with an infant dose that is half the normal dose. If a child is less than nine years 
old and is being is vaccinated for the first time a vaccination is repeated one month after the 
initial vaccination. It is recommended that family members of diabetics are also vaccinated. 
12.2. Pneumococcal pneumonia vaccine 
Pneumococcal pneumonia is an important cause of morbidity and mortality in patients with 
DM. Patients over 65 years and who had an additional pulmonary or cardiovascular problem 
are at an increased risk. This vaccine is recommended every five years. Half of the patients 
may suffer from local irritation at injection sites. The vaccine can be injected at the same time 
as other vaccines (e.g. influenza vaccine) but preferably in the other deltoid muscle. 
12.3. Hepatitis B vaccine 
Currently, there are studies examining recommendations for Hepatitis B vaccinations in 
DM. The Advisory Committee on Immunization Practices (ACIP) recommended that all of 
the unvaccinated adults aged 19 through 59 years with DM be vaccinated against hepatitis B 
[CDC 2011].  
13. Conflicts of interest 
The authors state that there are no conflicts of interest. 
Author details 
Hakan Demirci 
Department of Family Medicine, Sevket Yilmaz Training & Research Hospital, Bursa, Turkey 
Ilhan Satman 
Division of Endocrinology and Metabolism, Department of Internal Medicine, Istanbul Faculty of 
Medicine, Istanbul University, Istanbul, Turkey 
Yıldırım Çınar 
Department of Internal Medicine, Trakya University, Edirne, Turkey 
Nazan Bilgel 
Department of Family Medicine, Uludag University, Bursa, Turkey 
Acknowledgement 
The authors express their thanks to Mrs Nazlı Demirci (philologist) for her support in 
editing the English language of this chapter.  
 
Essentials of Diabetes Care in Family Practice 269 
14. References 
American Diabetes Association. (2012). Diagnosis and classification of diabetes mellitus. 
Diabetes Care. Vol. 35, No. 1, pp. 64-71. 
Amorosa LF, Lee EJ, Swee DE (2011). Diabetes Mellitus. Rakel & Rakel Textbook of Family 
Medicine 8th Edition. Chapter 34, pp. 731-755. 
Attarian S. (2011). Original articles on axonal neuropathy. Rev Neurol (Paris). Vol. 167, pp. 
951-954. 
Barnett PS, Braunstein GD. (2007). Diabetes Mellitus. Andreoli and Carpenter’s Cecil 
Essentials of medicine 7th Edition. Chapter 68, pp. 676-707. 
Budak Y, Demirci H, Akdogan M, Yavuz D. (2004). Erythrocyte membrane anionic charge in 
type 2 diabetic patients with retinopathy. BMC Ophthalmology 
http://www.biomedcentral.com/1471-2415/4/14. Accessed 2004 Oct. 
Centers of Disease Control and Prevention (CDC). (2011). Use of hepatitis B vaccination for 
adults with diabetes mellitus: recommendations of the Advisory Committee on 
Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. Vol. 60 No.50, pp. 
1709-11. 
Cimşit M, Uzun G, Yildiz S. (2009) Hyperbaric oxygen therapy as an anti-infective agent. 
Expert Rev Anti Infect Ther. Vol. 7, No. 8, pp. 1015-1028. 
Chobanian AV, Bakris GL, Black HR, et al. (2003). National Heart, Lung, and Blood Institute 
Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High 
Blood Pressure; National High Blood Pressure Education Program Coordinating 
Committee. The Seventh Report of the Joint National Committee on Prevention, 
Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 
Vol. 289, pp.2560–2572. 
Colquhoun AJ, Nicholson KG, Botha JL, Raymond NT. (1997). Effectiveness of influenza 
vaccine in reducing hospital admissions in people with diabetes. Epidemiol Infect. Vol. 
119, pp.335–341. 
Eknoyan G, Hostetter T, Bakris GL, et al. (2003). Proteinuria and other markers of chronic 
kidney disease: a position statement of the national kidney foundation (NKF) and the 
national institute of diabetes and digestive and kidney diseases (NIDDK). Am J Kidney 
Dis. Vol. 42, pp. 617–622. 
Grundy SM, Cleeman JI, Merz CN et al. (2004). National Heart, Lung, and Blood Institute; 
American College of Cardiology Foundation; American Heart Association. Implications 
of recent clinical trials for the National Cholesterol Education Program Adult Treatment 
Panel III guidelines. Circulation. Vol. 110, pp. 227–239.  
Heart Outcomes Prevention Evaluation Study Investigators. (2000). Effects of ramipril on 
cardiovascular and microvascular outcomes in people with diabetes mellitus: results of 
the HOPE study and MICRO-HOPE sub study. Lancet. Vol. 355, pp. 253–259. 
Klein R. (1995). Hyperglycemia and microvascular and macrovascular disease in diabetes. 
Diabetes Care. Vol. 18, pp. 258–268 
 
Diabetes Mellitus – Insights and Perspectives 270 
Kumar PR, Bhansali A, Ravikiran M. et al. (2010) Utility of glycated hemoglobin in 
diagnosing type 2 diabetes mellitus: a community-based study. J Clin Endocrinol 
Metab. Vol. 95, pp. 2832-2835. 
Leske MC, Wu SY, Hennis A, et al. Barbados Eye Study Group. (2005) Hyperglycemia, 
blood pressure, and the 9-year incidence of diabetic retinopathy: the Barbados Eye 
Studies. Ophthalmology. Vol. 112, pp.799-805. 
Nathan DM, Buse JB, Davidson MB et al. (2006) Management of hyperglycemia in type 2 
diabetes: A consensus algorithm for the initiation and adjustment of therapy: a 
consensus statement from ADA and EASD. Diabetes Care. Vol. 29, pp.1963-1972. 
Levey AS, Coresh J, Balk E, et al. (2003). National Kidney Foundation. National Kidney 
Foundation practice guidelines for chronic kidney disease: evaluation, classification, 
and stratification. Ann Intern Med. Vol. 139, pp. 137–147 
Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. (1999). Modification of Diet in 
Renal Disease Study Group. A more accurate method to estimate glomerular filtration 
rate from serum creatinine: a new prediction equation. Ann Intern Med. Vol. 130, 
pp.461–470. 
Satman I and TURDEP II study group report (2011). 48. Ulusal Diyabet Kongresi, Antalya. 
Sacks DB, Bruns DE, Goldstein DE, Maclaren NK, McDonald JM, Parrott M. (2002). 
Guidelines and recommendations for laboratory analysis in the diagnosis and 
management of diabetes mellitus. Clin Chem. Vol. 48, pp. 436-472. 
The Diabetic Retinopathy Study Research Group. (1976). Preliminary report on effects of 
photocoagulation therapy. Am J Ophthalmol. Vol. 81, pp. 383–396. 
Ziemer DC, Kolm p, Weintraub WS. et al. (2010) Glucose independent, black-white 
differences in hemoglobin A1c levels: a cross sectional analysis of 2 studies. Ann Intern 
Med. Vol. 153, pp. 770-777. 
